Clinical White Paper From the “Hadrontherapy for Life” Symposium - Clinical Expansion of Carbon Ion Facilities Worldwide

Sep 29, 2026

Uploaded by Finn

Carbon ion radiotherapy (CIRT) leverages the physical precision of charged particles and high-linear energy transfer (LET) biological effectiveness to improve control of radioresistant or anatomically complex tumors. This white paper, prepared from the “Hadrontherapy-for-Life” symposium in Caen (March 2025), compiles clinical evidence, operational strategies, and worldwide expansion plans. It reviews reported outcomes from major centers, summarizes key barriers, and outlines collaborative needs for registry harmonization, pragmatic trials, and economic sustainability.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages6

Reading Time15 min

AccessFree to download

Background and context

Objective

Methods and data sources

Results and key barriers

Conclusions

Introduction

Radiotherapy evolution and role of CIRT

International Journal of Particle Therapy 19 (2026) 101290 Contents lists available at ScienceDirect International Journal of Particle Therapy journal [homepage:](homepage: www.sciencedirect.com/journal/ijpt)[ www.sciencedirect.com/journal/ijpt](homepage: www.sciencedirect.com/journal/ijpt) Clinical White Paper From the “Hadrontherapy for Life” Symposium–Clinical Expansion of Carbon Ion Facilities Worldwide Juliette Thariat1,⁎, Virgille Letellier2, Tatsuya Ohno3, Shigeru Yamada4, Piero Fossati5, Ester Orlandi6, Semi Harrabi7, Jacques Balosso8, Gabriel Gaubert9, Siamak Haghdoost10, Jean Louis Habrand11 1 Department of Radiation Oncology, Comprehensive Cancer Center François Baclesse, ENSICAEN, CNRS/IN2P3, LPC Caen UMR6534, Université de Caen Normandie, Caen, France 2 Normandy Hadrontherapy, 14000 Caen, France 3 Department of Radiation Oncology, Gunma University Graduate School of Medicine, University Heavy Ion Medical Center, Maebashi, Gunma 3718511, Japan 4 QST Hospital, National Institutes for Quantum Science and Technology (QST), Chiba, Japan 5 Division Radiation Oncology, Karl Landsteiner University of Health Sciences, Krems an der Donau, Austria 6 Radiation Oncology Unit, Clinical Department, CNAO National Center for Oncological Hadrontherapy, Pavia, Italy 7 Heidelberg Ion-Beam Therapy Center (HIT), Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany 8 Centre Hospitalier Universitaire Grenoble Alpes, Maquis du Grésivaudan, La Tronche, France 9 CYCLHAD, Multi-ion Hadron Therapy Center, Caen, France 10 Université Caen Normandie, Univ Rouen Normandie, Normandie Univ, ABTE UR4651, F-14000 Caen, France 11 Department of Radiation Oncology, Comprehensive Cancer Center François Baclesse, Caen, France A R T I C L E I N F O Keywords: Carbon ion radiotherapy Hadrontherapy Hypofractionation Clinical expansion Global collaboration Evidence A B S T R A C T Background: Carbon ion radiotherapy (CIRT) combines the physical precision of charged particles with highlinear energy transfer (LET) biological effectiveness, enabling superior control of radioresistant or anatomically complex tumors. Initially developed in Japan, CIRT is slowly expanding globally with increasing institutional and clinical maturity. Objective: To summarize current clinical evidence, operational strategies, and expansion plans for carbon ion facilities worldwide, as discussed during the “Hadrontherapy-for-Life” symposium held in Caen, France (March 2025). Methods: This white paper compiles presentations and institutional reports from major CIRT centers in Japan (QST, Gunma), Europe (HIT, CNAO, MedAustron, Cyclhad), and other emerging sites. Data sources include institutional registries, peer-reviewed studies, and national frameworks for hadrontherapy development. Results: Over 50,000 patients have received CIRT worldwide. Japan remains the leading contributor through the J-CROS network, emphasizing registry-based research, hypofractionation, and treatment of mobile tumors. European centers adopt translational programs aimed at further exploiting biological properties of carbon and helium ions. Major barriers include heterogeneous dose-modeling (local effect model vs modified microdosimetric kinetic model), limited image guidance, lack of standardized indications, and funding disparities. Ongoing efforts emphasize registry harmonization, pragmatic trials, and cost-effectiveness modeling. New multiion facilities such as Cyclhad (Caen) aim to propose multi-ion therapy, increase the level of evidence for clinical use, and promote research. Conclusions: CIRT is transitioning from pioneering programs to a coordinated global network. Collaborative initiatives and shared data platforms are essential to establish evidence-based indications, optimize biological modeling, and ensure economic sustainability. The “Hadrontherapy-for-Life” initiative calls for a strategic step toward internatio

FAQs

What is the main purpose of this clinical white paper?

To summarize current clinical evidence, operational strategies, and expansion plans for carbon ion facilities worldwide based on discussions at the “Hadrontherapy for Life” symposium in Caen (March 2025).

How does carbon ion radiotherapy differ from conventional photon radiotherapy?

CIRT combines charged-particle precision with high-LET biological effectiveness, supporting improved control of radioresistant or anatomically complex tumors where photons may underperform.

What barriers and challenges are highlighted for global CIRT expansion?

Key barriers include heterogeneous dose modeling approaches, limited image guidance, lack of standardized indications, and funding disparities across regions.

Sep 29, 2026

Uploaded by Finn